Anticipated $0.58 EPS for Abbott Laboratories (ABT) on April, 18

April 17, 2018 - By Russell Jones

Abbott Laboratories (NYSE:ABT) Corporate Logo
During Q4 2017 the big money sentiment increased to 0.91. That’s change of 0.04, from 2017Q3’s 0.87. 52 investors sold all, 558 reduced holdings as Abbott Laboratories ratio is positive. 430 rose stakes while 123 funds took stakes. Funds hold 1.22 billion shares thus 0.64% more from 2017Q3’s 1.21 billion shares.
Ballentine Prtn Limited Liability Com owns 8,923 shs for 0.03% of their capital. First Hawaiian Bank & Trust, Hawaii-based fund reported 13,767 shs. Sumitomo Mitsui Trust invested in 5.06M shs. Schmidt P J Investment Management has 0.77% invested in Abbott Laboratories (NYSE:ABT). 7,255 are owned by Obermeyer Wood Inv Counsel Lllp. Wetherby Asset Mgmt has 0.3% invested in Abbott Laboratories (NYSE:ABT) for 38,471 shs. Pictet Fincl Bank And Trust Ltd holds 47,850 shs or 0.8% of its capital. Icon Advisers Communication, a Colorado-based fund reported 66,300 shs. 192,677 are owned by Public Sector Pension Investment Board. Jolley Asset Management Limited Liability reported 1.17% of its capital in Abbott Laboratories (NYSE:ABT). The California-based Cornerstone Capital has invested 3.05% in Abbott Laboratories (NYSE:ABT). Poplar Forest Cap Lc has 1.21M shs for 5.49% of their capital. Notis invested 2.94% of its capital in Abbott Laboratories (NYSE:ABT). Gam Holdg Ag has 10,374 shs for 0.02% of their capital. M&R Mgmt invested in 23,587 shs.

Abbott Laboratories registered $28.95 million net activity with 1 insider purchase and 19 insider sales since October 23, 2017. Fussell Stephen R also sold $3.36M worth of Abbott Laboratories (NYSE:ABT) shs. 1,645 shs were sold by BIRD ROGER, worth $96,728 on Wednesday, February 28. Salvadori Daniel Gesua Sive had sold 905 shs worth $53,369. On Wednesday, February 28 Contreras Jaime also sold $375,381 worth of Abbott Laboratories (NYSE:ABT). STARKS DANIEL J bought $2.43M worth of stock or 40,037 shs. 2,100 shs valued at $126,559 were sold by Bracken Sharon J on Monday, March 5.

Investors wait Abbott Laboratories (NYSE:ABT)’s quarterly earnings on April, 18., according to RTT. Analysts expect change of 20.83 % or $0.10 from previous year’s $0.48 earnings per share compared to current’s $0.58 earnings per share. If reported the P/E will be 25.55 with $1.01 billion profit. After $0.74 earnings per share was revealed last quarter, analysts now see negative EPS growth of -21.62 % for Abbott Laboratories. ABT reached $59.27 on during the last trading session after $0.78 change.Currently Abbott Laboratories is uptrending after 34.85% change in last April 17, 2017. ABT has 6.81 million shares volume. ABT outperformed by 23.30% the S&P 500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Total analysts of 15 have positions in Abbott Labs (NYSE:ABT) as follows: 13 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 87%. The firm has $80.0 highest while $5 is the lowest [Target]. The average target $69.54 is 17.33% above the last ($59.27) price. Since October 18, 2017 according to StockzIntelligence Inc Abbott Labs has 26 analyst reports. In Tuesday, January 30 report Citigroup maintained the stock with “Neutral” rating. In Wednesday, October 18 report Jefferies maintained the stock with “Buy” rating. On Thursday, January 25 Barclays Capital maintained Abbott Laboratories (NYSE:ABT) rating. Barclays Capital has “Overweight” rating and $70 target. The stock rating was maintained by RBC Capital Markets with “Buy” on Thursday, October 19. On Thursday, October 19 the rating was maintained by Citigroup with “Neutral”. On Tuesday, January 2 the firm earned “Overweight” rating by JP Morgan. On Wednesday, January 24 the rating was maintained by Jefferies with “Buy”. On Thursday, October 19 the company was maintained by BMO Capital Markets. In Wednesday, October 18 report Cowen & Co maintained the stock with “Buy” rating. On Thursday, January 25 the firm earned “Overweight” rating by Morgan Stanley.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is valued at $103.51 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.The P/E ratio is 220.33. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.